VIDEO: Supplemental treatment not needed in two-thirds of eyes that received EYP-1901
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses data from the DAVIO 2 trial investigating EYP-1901 for the treatment of wet age-related macular degeneration.
After receiving three loading doses of Eylea (aflibercept, Regeneron), patients were randomly assigned to receive either 3 mg or 2 mg EYP-1901 (vorolanib, EyePoint Pharmaceuticals) or bimonthly Eylea.
According to Abbey, at 6 months, about two-thirds of eyes that received EYP-1901 did not require supplemental treatment, and there were no significant differences in visual acuity or central subfield thickness between the three groups.
Collapse
Sheth V. Assessing supplemental injection use across groups in the phase 2 DAVIO 2 trial of EYP-1901 vs aflibercept in wet age-related macular degeneration. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts